Amrutanjan Health Care Limited (AMRUTANJAN)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 15 July 2026
₹533.95 ↓ 25.91% (1Y)

🎯 Key Takeaways

  • Amrutanjan Health Care Limited is in a governance and board stabilization phase, with recent shareholder approvals focused on strengthening its independent director bench. The company shows no active operational or financial performance narrative in recent filings, with emphasis on regulatory compliance and leadership continuity rather than growth initiatives or financial results.
  • ⚠️ Limited financial transparency: The absence of recent financial results or management discussion on performance creates uncertainty around operational
Market Cap
₹1,604
P/E Ratio
27.7
Div Yield
0.00%
Promoter
0.0%

📖 The Story

Amrutanjan Health Care Limited is in a governance and board stabilization phase, with recent shareholder approvals focused on strengthening its independent director bench. The company shows no active operational or financial performance narrative in recent filings, with emphasis on regulatory compliance and leadership continuity rather than growth initiatives or financial results.

📰 What's Happening

In the last three quarters, the company has centered on board appointments, with shareholders approving the five-year term of Dr. Ramaswami Krishnan as Non-Executive Independent Director (effective May 8, 2026) and the re-appointment of Mr. Swayambunathan Muralidharan for a second term (effective June 29, 2026). These appointments were passed via both remote e-voting and postal ballot, reflecting strong shareholder consensus. The process was governed by SEBI-mandated voting procedures, with results confirmed in filings dated May 18, June 19, and June 19, 2026. Management has not announced new business lines or expansions, but emphasized that the appointments enhance governance expertise and board continuity.

Source: Stock Announcements

🔮 Management Outlook & What's Next

Management has not provided forward-looking operational or financial guidance in the recent filings. The only forward-looking statements relate to the effective dates of director appointments and the procedural timeline for shareholder voting. No commentary on business outlook, revenue expectations, or investment plans was included in the disclosed documents.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company MCap (₹ Cr) P/E ROCE ROE D/E
Sun Pharmaceutical Industries Limited 4.51 L Cr 41.3 20.3% 15.1% 0.03
Divi's Laboratories Limited 1.79 L Cr 72.4 22.1% 16.6% 0.00
Torrent Pharmaceuticals Limited 1.49 L Cr 80.1
Cipla Limited 1.16 L Cr 25.4 19.4% 14.6% 0.00
Dr. Reddy's Laboratories Limited 1.12 L Cr 20.0 19.7% 16.6% 0.12
Lupin Limited 1.04 L Cr 36.2
Mankind Pharma Limited 1.03 L Cr 49.2
Zydus Lifesciences Limited 1.02 L Cr 22.5
Aurobindo Pharma Limited 87,806 25.3
Laurus Labs Limited 71,455 356.8

🔗 Peer Stock Analyses

⚠️ Risk Factors

1. Limited financial transparency: The absence of recent financial results or management discussion on performance creates uncertainty around operational health. 2. Governance dependency: With board strength tied to independent directors appointed via shareholder vote, future governance stability may hinge on continued shareholder confidence and timely re-appointments.

📋 Recent Filings

🧠 Analyst's Read

The company is currently in a quiet phase dominated by regulatory compliance and board continuity efforts, with no active financial or operational narrative emerging. Investors should monitor the timely release of future financial results and any strategic commentary following the stabilization of the board structure.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

Sign Up Free — Unlock Full Analysis

2 free AI queries per day.

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when AMRUTANJAN files new disclosures

Track AMRUTANJAN filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AMRUTANJAN — Free

Free account · 2 AI queries/day